Breaking News

Aptevo Spin-off Receives $20M Emergent Payment

Final payment funds newly-launched oncology and hematology-focused company

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Aptevo Therapeutics Inc. has received a $20 million payment from Emergent BioSolutions pursuant to a promissory note granted as a result of the spin-off of Aptevo from Emergent last August.   Emergent has provided a total of $65 million in cash contributions to fund Aptevo’s operations as a newly-launched oncology and hematology-focused company. Aptevo has a pipeline of commercial, clinical and preclinical assets and a bispecific technology platform, ADAPTIR, focused on the development of immu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters